Insufficient scRNA-seq data for expression of KLK8 at single-cell level.
Insufficient scRNA-seq data for expression of KLK8 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 0% | 0 | 0 / 180 | 97% | 35.79 | 417 / 430 |
esophagus | 39% | 1620.42 | 560 / 1445 | 56% | 9.80 | 103 / 183 |
skin | 72% | 2475.51 | 1294 / 1809 | 9% | 2.14 | 43 / 472 |
pancreas | 0% | 0 | 0 / 328 | 43% | 5.93 | 76 / 178 |
breast | 29% | 170.46 | 134 / 459 | 11% | 1.61 | 121 / 1118 |
uterus | 5% | 48.73 | 8 / 170 | 33% | 6.80 | 150 / 459 |
tonsil | 0% | 0 | 0 / 0 | 33% | 7.47 | 15 / 45 |
lung | 0% | 0.59 | 1 / 578 | 24% | 2.77 | 272 / 1155 |
intestine | 0% | 0 | 0 / 966 | 20% | 2.30 | 106 / 527 |
stomach | 1% | 2.39 | 2 / 359 | 17% | 1.73 | 49 / 286 |
bladder | 0% | 0 | 0 / 21 | 18% | 3.01 | 89 / 504 |
adipose | 14% | 62.18 | 164 / 1204 | 0% | 0 | 0 / 0 |
thymus | 0% | 0 | 0 / 653 | 8% | 1.89 | 51 / 605 |
adrenal gland | 0% | 1.22 | 1 / 258 | 0% | 0 | 0 / 230 |
liver | 0% | 0 | 0 / 226 | 0% | 0.02 | 1 / 406 |
kidney | 0% | 0 | 0 / 89 | 0% | 0.04 | 2 / 901 |
muscle | 0% | 0.57 | 1 / 803 | 0% | 0 | 0 / 0 |
heart | 0% | 0.34 | 1 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 0% | 1.41 | 1 / 1335 | 0% | 0 | 0 / 0 |
brain | 0% | 0.10 | 1 / 2642 | 0% | 0 | 0 / 705 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
prostate | 0% | 0 | 0 / 245 | 0% | 0 | 0 / 502 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0048812 | Biological process | neuron projection morphogenesis |
GO_0007613 | Biological process | memory |
GO_0050807 | Biological process | regulation of synapse organization |
GO_0050808 | Biological process | synapse organization |
GO_0009611 | Biological process | response to wounding |
GO_0006508 | Biological process | proteolysis |
GO_0043616 | Biological process | keratinocyte proliferation |
GO_0097180 | Cellular component | serine protease inhibitor complex |
GO_0005615 | Cellular component | extracellular space |
GO_0030141 | Cellular component | secretory granule |
GO_0005576 | Cellular component | extracellular region |
GO_0005737 | Cellular component | cytoplasm |
GO_0005515 | Molecular function | protein binding |
GO_0004252 | Molecular function | serine-type endopeptidase activity |
Gene name | KLK8 |
Protein name | Kallikrein-8 isoform 12 Kallikrein-8 isoform 9 KLK8 protein type 1 Kallikrein-8 isoform 13 Kallikrein-related peptidase 8 transcript variant 15 Kallikrein-8 isoform 8 Kallikrein 8 KLK8 protein type 2 Kallikrein-8 (hK8) (EC 3.4.21.118) (Neuropsin) (NP) (Ovasin) (Serine protease 19) (Serine protease TADG-14) (Tumor-associated differentially expressed gene 14 protein) Kallikrein-8 isoform 10 Kallikrein-8 isoform 11 Kallikrein-8 isoform 6 Kallikrein related peptidase 8 Kallikrein-8 isoform 7 |
Synonyms | TADG14 UNQ283/PRO322 HNP NRPN NP PRSS19 |
Description | FUNCTION: Serine protease which is capable of degrading a number of proteins such as casein, fibrinogen, kininogen, fibronectin and collagen type IV. Also cleaves L1CAM in response to increased neural activity. Induces neurite outgrowth and fasciculation of cultured hippocampal neurons. Plays a role in the formation and maturation of orphan and small synaptic boutons in the Schaffer-collateral pathway, regulates Schaffer-collateral long-term potentiation in the hippocampus and is required for memory acquisition and synaptic plasticity. Involved in skin desquamation and keratinocyte proliferation. Plays a role in the secondary phase of pathogenesis following spinal cord injury. . |
Accessions | A0A2H4GDC2 ENST00000695909.1 [O60259-1] M0R390 ENST00000347619.8 [O60259-3] ENST00000320838.9 [O60259-4] ENST00000600767.5 [O60259-1] Q2XQG5 B3FQ94 A0A2H4GDC1 A0A2H4GDA8 ENST00000594669.1 ENST00000291726.11 ENST00000595238.1 ENST00000391806.6 [O60259-2] A0A2H4GDB8 ENST00000593490.1 [O60259-4] A0A2H4GDB9 O60259 A0A2H4GDB3 A0A2H4GDC0 B3FQ95 A0A2H4GDC4 M0R231 A0A0A0MQY9 A0A2I2MQ02 |